In the DLBCL controls, the median OS was 40 months, and high proportions of PD-L1+ TILs or PD-L2+ tumor cells and TILs did not affect OS in patients with RA-DLBCL or DLBCL controls (Table 5). This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.